{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:22Z","timestamp":1792931962905,"version":"4.5.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00146-1","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:04:13Z","timestamp":1781330653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel treatment strategies in acute myeloid leukemia"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-9963","authenticated-orcid":false,"given":"Shailesh","family":"Simkhada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utsav","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajwal","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"146_CR1","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(23)00464-6.","journal-title":"Lancet"},{"key":"146_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"146_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"387","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, et al. Ivosidenib plus azacitidine in IDH1-mutated acute myeloid leukemia (AGILE). N Engl J Med. 2022;387:1519\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2117344.","journal-title":"N Engl J Med"},{"issue":"15","key":"146_CR4","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42(15):1766\u201375. https:\/\/doi.org\/10.1200\/JCO.23.02474.","journal-title":"J Clin Oncol"},{"key":"146_CR5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMx220003","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated acute myeloid leukemia (ADMIRAL). N Engl J Med. 2019;381:1728\u201340. https:\/\/doi.org\/10.1056\/NEJMx220003.","journal-title":"N Engl J Med"},{"key":"146_CR6","doi-asserted-by":"publisher","unstructured":"Negotei C, Colita A, Mitu I, Lupu AR, Lapadat ME, Popovici CE, et al. A review of FLT3 kinase inhibitors in AML. J Clin Med. 2023;12(20):6429, 6429. https:\/\/doi.org\/10.3390\/jcm12206429.","DOI":"10.3390\/jcm12206429"},{"key":"146_CR7","doi-asserted-by":"publisher","unstructured":"Zhao Y, Zhao R, et al. Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials. Front Pharmacol. 2024;15:1294668, 1294668. https:\/\/doi.org\/10.3389\/fphar.2024.1294668.","DOI":"10.3389\/fphar.2024.1294668"},{"key":"146_CR8","doi-asserted-by":"publisher","unstructured":"Novatcheva ED, et al. FMS-like tyrosine kinase 3 inhibitors for acute myeloid leukemia. Pharmacol Ther. 2022;234:108042. https:\/\/doi.org\/10.1016\/j.clml.2021.09.002.","DOI":"10.1016\/j.clml.2021.09.002"},{"key":"146_CR9","doi-asserted-by":"publisher","unstructured":"Kiyoi H. FLT3 mutations in acute myeloid leukemia. Cancer Sci. 2020;111:3122\u201330. https:\/\/doi.org\/10.1111\/cas.14274.","DOI":"10.1111\/cas.14274"},{"key":"146_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia. Front Oncol. 2020;10:612880. https:\/\/doi.org\/10.3389\/fonc.2020.612880.","journal-title":"Front Oncol"},{"issue":"8","key":"146_CR11","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3390\/cancers15082312","volume":"15","author":"K Fedorov","year":"2023","unstructured":"Fedorov K, et al. Targeting FLT3 mutations. Cancers (Basel). 2023;15(8):2312. https:\/\/doi.org\/10.3390\/cancers15082312.","journal-title":"Cancers (Basel)"},{"key":"146_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, et al. FLT3-mutated acute myeloid leukemia: current practices. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"issue":"5","key":"146_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, et al. Midostaurin plus chemotherapy for FLT3-mutated acute myeloid leukemia (RATIFY). N Engl J Med. 2017;377(5):454\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1614359.","journal-title":"N Engl J Med"},{"issue":"6","key":"146_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","volume":"16","author":"M Larrosa-Garcia","year":"2017","unstructured":"Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2017;16(6):991\u20131001. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0876.","journal-title":"Leukemia"},{"issue":"1","key":"146_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru MT, et al. Targeting FLT3 and resistance. J Hematol Oncol. 2020;13(1):155. https:\/\/doi.org\/10.1186\/s13045-020-00992-1.","journal-title":"J Hematol Oncol"},{"key":"146_CR16","first-page":"3161","volume":"4","author":"MT Voso","year":"2020","unstructured":"Voso MT, et al. Midostaurin safety update. Blood Adv. 2020;4:3161\u20139.","journal-title":"Blood Adv"},{"key":"146_CR17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","volume":"35","author":"RT Maziarz","year":"2021","unstructured":"Maziarz RT, et al. Midostaurin after allogeneic hematopoietic cell transplantation in FLT3-ITD acute myeloid leukemia. Leukemia. 2021;35:201\u201311.","journal-title":"Leukemia"},{"key":"146_CR18","first-page":"2368","volume":"55","author":"RT Maziarz","year":"2020","unstructured":"Maziarz RT, et al. Midostaurin maintenance following allogeneic transplantation for FLT3-ITD acute myeloid leukemia. Bone Marrow Transplant. 2020;55:2368\u201377.","journal-title":"Bone Marrow Transplant"},{"key":"146_CR19","doi-asserted-by":"publisher","unstructured":"Cortes J. Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD\u2013positive AML. J Hematol Oncol. 2024;17:111, 111. https:\/\/doi.org\/10.1186\/s13045-024-01617-7.","DOI":"10.1186\/s13045-024-01617-7"},{"issue":"Suppl 1","key":"146_CR20","volume":"144","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, et al. Quizartinib maintenance and survival outcomes in FLT3-ITD acute myeloid leukemia. Blood. 2024;144(Suppl 1):207305.","journal-title":"Blood"},{"key":"146_CR21","doi-asserted-by":"publisher","unstructured":"Montesinos P, Rodr\u00edguez-Veiga R, Bergua JM, Algarra JL, Botella C, Rodr\u00edguez-Arbol\u00ed E, et al. Quizartinib for newly diagnosed FLT3-internal tandem duplication\u2013negative acute myeloid leukemia: the randomized, double-blind, placebo-controlled, phase 2 QUIWI study. J Clin Oncol. 2026;44(1):42\u201353. https:\/\/doi.org\/10.1200\/JCO-25-01841.","DOI":"10.1200\/JCO-25-01841"},{"key":"146_CR22","volume":"113","author":"AE Perl","year":"2022","unstructured":"Perl AE, et al. ADMIRAL long-term follow-up. Leuk Res. 2022;113:106770.","journal-title":"Leuk Res"},{"key":"146_CR23","doi-asserted-by":"publisher","unstructured":"Wang J, Jiang B, Li J, Liu L, Du X, Jiang H, et al. Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia. Leukemia. 2024;38:2410\u20138. https:\/\/doi.org\/10.1038\/s41375-024-02382-9.","DOI":"10.1038\/s41375-024-02382-9"},{"issue":"17","key":"146_CR24","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, et al. Gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3-mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845\u201357. https:\/\/doi.org\/10.1182\/blood.2021014586.","journal-title":"Blood"},{"issue":"26","key":"146_CR25","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.19.03345","volume":"38","author":"A Burchert","year":"2020","unstructured":"Burchert A, et al. Sorafenib maintenance after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2020;38(26):2993\u20133002. https:\/\/doi.org\/10.1200\/JCO.19.03345.","journal-title":"J Clin Oncol."},{"key":"146_CR26","first-page":"e47","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, et al. Long-term sorafenib maintenance. Lancet Haematol. 2023;10:e47\u201356.","journal-title":"Lancet Haematol"},{"key":"146_CR27","unstructured":"ClinicalTrials.gov. A randomized, open-label phase 3 study evaluating safety and efficacy of venetoclax in combination with azacitidine after allogeneic stem cell transplantation in subjects with acute myeloid leukemia (AML) (VIALE-T). ClinicalTrials.gov identifier: NCT04161885. Sponsor: AbbVie. Last update posted October 6, 2025. Accessed 5 June 2026."},{"key":"146_CR28","doi-asserted-by":"publisher","unstructured":"Wang ES, Goldberg AD, Walter RB, Collins R, Stone RM. Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML. J Clin Oncol. 2022;40:7007, 7007. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7007.","DOI":"10.1200\/JCO.2022.40.16_suppl.7007"},{"key":"146_CR29","doi-asserted-by":"publisher","unstructured":"Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019;10:244, 244. https:\/\/doi.org\/10.1038\/s41467-018-08263-x.","DOI":"10.1038\/s41467-018-08263-x"},{"issue":"26","key":"146_CR30","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1200\/JCO.22.02721","volume":"41","author":"KW Pratz","year":"2023","unstructured":"Pratz KW, et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase Ib study in patients with newly diagnosed AML. J Clin Oncol. 2023;41(26):4236\u201346. https:\/\/doi.org\/10.1200\/JCO.22.02721.","journal-title":"J Clin Oncol"},{"key":"146_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8080245","author":"M Eguchi","year":"2020","unstructured":"Eguchi M, et al. Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia. Biomedicines. 2020. https:\/\/doi.org\/10.3390\/biomedicines8080245.","journal-title":"Biomedicines"},{"key":"146_CR32","doi-asserted-by":"publisher","unstructured":"Desikan SP, Daver N, DiNardo CD, Kadia TM, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022;12:91, 91. https:\/\/doi.org\/10.1038\/s41408-022-00687-5.","DOI":"10.1038\/s41408-022-00687-5"},{"issue":"4","key":"146_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","volume":"31","author":"G Ghiaur","year":"2017","unstructured":"Ghiaur G, Levis M. Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment. Hematol Oncol Clin North Am. 2017;31(4):681\u201392. https:\/\/doi.org\/10.1016\/j.hoc.2017.04.005.","journal-title":"Hematol Oncol Clin North Am"},{"key":"146_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-cancerbio-062822-025055","volume":"8","author":"MF Jones","year":"2024","unstructured":"Jones MF, Smith CC. Mechanisms of resistance to targeted therapies in AML. Annu Rev Cancer Biol. 2024;8:81\u201396. https:\/\/doi.org\/10.1146\/annurev-cancerbio-062822-025055.","journal-title":"Annu Rev Cancer Biol"},{"key":"146_CR35","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, et al. Venetoclax plus gilteritinib. J Clin Oncol. 2022;40:4048\u201359.","journal-title":"J Clin Oncol"},{"key":"146_CR36","volume":"130","author":"Q Fu","year":"2024","unstructured":"Fu Q, et al. Gilteritinib-based triplets. Leuk Res. 2024;130:107055.","journal-title":"Leuk Res"},{"key":"146_CR37","doi-asserted-by":"publisher","unstructured":"Marrero-Le\u00f3n WD, Cintron-Colon HR, Torres-Cintr\u00f3n CR, Delgado-L\u00f3pez N, Arroyo-Hern\u00e1ndez G, Grau-Garc\u00eda V, et al. Triplet therapy for FLT3-mutated acute myeloid leukemia in Puerto Rico: a retrospective study. J Clin Oncol. 2025;43(16 Suppl):e18534. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e18534.","DOI":"10.1200\/JCO.2025.43.16_suppl.e18534"},{"key":"146_CR38","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva M, et al. FLT3 mutations and venetoclax outcomes. Clin Cancer Res. 2022;28:2744\u201352.","journal-title":"Clin Cancer Res"},{"key":"146_CR39","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Molecular response patterns after venetoclax. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"146_CR40","doi-asserted-by":"publisher","unstructured":"Short NJ, DiNardo CD, Daver N, Bose P, Pemmaraju N, Borthakur G, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42(13):1499\u2013508. https:\/\/doi.org\/10.1200\/JCO.23.01911.","DOI":"10.1200\/JCO.23.01911"},{"key":"146_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1182\/blood-2023-186699","volume":"142","author":"M Yilmaz","year":"2023","unstructured":"Yilmaz M, Muftuoglu M, DiNardo CD, Kadia TM, Konopleva MY, Borthakur G, et al. Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. Blood. 2023;142:158. https:\/\/doi.org\/10.1182\/blood-2023-186699.","journal-title":"Blood"},{"key":"146_CR42","doi-asserted-by":"publisher","unstructured":"Carter BZ, Mak PY, Tao W, Ostermann LB, Mak DH, Ke B, et al. Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1\/FLT3-ITD\/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica. 2023;108(9):2513\u20139. https:\/\/doi.org\/10.3324\/haematol.2022.281927.","DOI":"10.3324\/haematol.2022.281927"},{"issue":"21","key":"146_CR43","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1182\/blood.2020005037","volume":"136","author":"MM Dzama","year":"2020","unstructured":"Dzama MM, Steiner M, Rausch J, Sasca D, Sch\u00f6nfeld J, Kunz K, et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood. 2020;136(21):2442\u201356. https:\/\/doi.org\/10.1182\/blood.2020005037.","journal-title":"Blood"},{"key":"146_CR44","doi-asserted-by":"publisher","unstructured":"Nadiminti KVG, McCracken CE, Altman JK, Zeidner JF. Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead. J Hematol Oncol. 2024;17(1):113, 113. https:\/\/doi.org\/10.1186\/s13045-024-01632-8.","DOI":"10.1186\/s13045-024-01632-8"},{"key":"146_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, et al. Oncometabolite 2-hydroxyglutarate. Cancer Cell. 2011;19:17\u201330.","journal-title":"Cancer Cell"},{"key":"146_CR46","unstructured":"Watts JM, et al. Olutasidenib alone or with azacitidine. 2022."},{"key":"146_CR47","unstructured":"Ye D, et al. R-2-hydroxyglutarate. 2013."},{"key":"146_CR48","unstructured":"Norsworthy KJ, et al. Differentiation syndrome with IDH inhibitors. 2020."},{"issue":"20","key":"146_CR49","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","volume":"9","author":"P Montesinos","year":"2025","unstructured":"Montesinos P, et al. Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. Blood Adv. 2025;9(20):5177\u201389. https:\/\/doi.org\/10.1182\/bloodadvances.2025016399.","journal-title":"Blood Adv"},{"key":"146_CR50","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, et al. Ivosidenib induces durable remissions in IDH1-mutated acute myeloid leukemia ineligible for intensive chemotherapy. Blood. 2020;135:463\u201371.","journal-title":"Blood"},{"issue":"1","key":"146_CR51","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1182\/hematology.2023000429","volume":"2023","author":"S Venugopal","year":"2023","unstructured":"Venugopal S, Watts J. The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy. Hematol Am Soc Hematol Educ Program. 2023;2023(1):192\u20137. https:\/\/doi.org\/10.1182\/hematology.2023000429.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"146_CR52","unstructured":"ClinicalTrials.gov. Ivosidenib and azacitidine with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS\/AML considered ineligible for intensive chemotherapy. ClinicalTrials.gov identifier: NCT07075016. Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland. Available at: ClinicalTrials.gov. Accessed 5 June 2026."},{"issue":"13","key":"146_CR53","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","volume":"7","author":"S de Botton","year":"2023","unstructured":"de Botton S, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117\u201327. https:\/\/doi.org\/10.1182\/bloodadvances.2022009411.","journal-title":"Blood Adv"},{"key":"146_CR54","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood.2021014901","volume":"141","author":"S de Botton","year":"2023","unstructured":"de Botton S, et al. Enasidenib versus conventional care in older patients with relapsed or refractory IDH2-mutated acute myeloid leukemia. Blood. 2023;141:156\u201367.","journal-title":"Blood"},{"issue":"11","key":"146_CR55","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22(11):1597\u2013608. https:\/\/doi.org\/10.1016\/S1470-2045(21)00494-0.","journal-title":"Lancet Oncol"},{"issue":"13","key":"146_CR56","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood.2020007233","volume":"137","author":"EM Stein","year":"2021","unstructured":"Stein EM, DiNardo CD, Fathi AT, Mims AS, Pratz KW, Savona MR, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021;137(13):1792\u2013803. https:\/\/doi.org\/10.1182\/blood.2020007233.","journal-title":"Blood"},{"key":"146_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Kadia TM, et al. Ivosidenib plus venetoclax with or without azacitidine in IDH1-mutated acute myeloid leukemia. Blood Cancer Discov. 2023;4:36\u201349.","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"146_CR58","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, et al. Enasidenib in IDH2-mutated acute myeloid leukemia. Blood. 2017;130(6):722\u201331. https:\/\/doi.org\/10.1182\/blood-2017-04-779405.","journal-title":"Blood."},{"key":"146_CR59","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, et al. Azacitidine \u00b1 enasidenib. Lancet Oncol. 2021;22:1597\u2013608.","journal-title":"Lancet Oncol"},{"key":"146_CR60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","volume":"12","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, et al. Enasidenib plus azacitidine. Blood Cancer J. 2022;12:10.","journal-title":"Blood Cancer J"},{"key":"146_CR61","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","volume":"137","author":"RM Stone","year":"2021","unstructured":"Stone RM, et al. IDH inhibitors with intensive chemotherapy. Blood. 2021;137:1792\u2013803.","journal-title":"Blood"},{"key":"146_CR62","first-page":"50","volume":"2020","author":"AW Roberts","year":"2020","unstructured":"Roberts AW. BCL-2 inhibition in hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2020;2020:50\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"146_CR63","doi-asserted-by":"publisher","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, et al. Venetoclax in acute myeloid leukemia: molecular basis, evidences for preclinical and clinical efficacy and strategies to target resistance. Cancers (Basel). 2021;13(15):3888. https:\/\/doi.org\/10.3390\/cancers13153888.","DOI":"10.3390\/cancers13153888"},{"key":"146_CR64","doi-asserted-by":"publisher","unstructured":"Cao Q, Wang Y, Ma H, Wang C, Zhang W, Duan Y, et al. Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a review. Signal Transduct Target Ther. 2023;8(1):429. https:\/\/doi.org\/10.1038\/s41392-023-01631-6.","DOI":"10.1038\/s41392-023-01631-6"},{"issue":"8","key":"146_CR65","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, et al. Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022;40(8):855\u201365. https:\/\/doi.org\/10.1200\/JCO.21.01546.","journal-title":"J Clin Oncol"},{"key":"146_CR66","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Ten-day decitabine plus venetoclax. Lancet Haematol. 2020;7:e724\u201336.","journal-title":"Lancet Haematol"},{"key":"146_CR67","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, et al. Venetoclax plus low-dose cytarabine. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"issue":"10","key":"146_CR68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","volume":"11","author":"AH Wei","year":"2021","unstructured":"Wei AH, et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer J. 2021;11(10):163. https:\/\/doi.org\/10.1038\/s41408-021-00555-8.","journal-title":"Blood Cancer J"},{"issue":"33","key":"146_CR69","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X, et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022;40(33):3848\u201357. https:\/\/doi.org\/10.1200\/JCO.21.02823.","journal-title":"J Clin Oncol"},{"issue":"25","key":"146_CR70","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2021;39(25):2768\u201378. https:\/\/doi.org\/10.1200\/JCO.20.03736.","journal-title":"J Clin Oncol"},{"key":"146_CR71","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, et al. Venetoclax plus FLAG-IDA. J Clin Oncol. 2021;39:2768\u201378.","journal-title":"J Clin Oncol"},{"key":"146_CR72","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1182\/blood-2022-167931","volume":"140","author":"PK Reville","year":"2022","unstructured":"Reville PK, Kantarjian H, Borthakur G, Yilmaz M, Daver N, Short NJ, et al. Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA) as induction therapy in patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;140:1702\u20134. https:\/\/doi.org\/10.1182\/blood-2022-167931.","journal-title":"Blood"},{"issue":"8","key":"146_CR73","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/ajh.27723","volume":"100","author":"TM Kadia","year":"2025","unstructured":"Kadia TM, et al. A phase 2 trial of CPX-351 combined with venetoclax in relapsed or refractory acute myeloid leukemia. Am J Hematol. 2025;100(8):1365\u201373. https:\/\/doi.org\/10.1002\/ajh.27723.","journal-title":"Am J Hematol"},{"key":"146_CR74","unstructured":"ClinicalTrials.gov. Venetoclax and azacitidine versus induction chemotherapy for the treatment of fit adults with newly diagnosed acute myeloid leukemia. ClinicalTrials.gov identifier: NCT04801797. Sponsor: Dana-Farber Cancer Institute. Accessed 5 June 2026."},{"key":"146_CR75","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2025-6","volume":"146","author":"AT Fathi","year":"2025","unstructured":"Fathi AT, Perl A, Fell G, Jonas B, Ragon B, Mims A, et al. Results from PARADIGM: a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. 2025;146:6. https:\/\/doi.org\/10.1182\/blood-2025-6.","journal-title":"Blood"},{"issue":"23","key":"146_CR76","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1200\/JCO-25-00914","volume":"43","author":"JF Zeidner","year":"2025","unstructured":"Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, et al. Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML. J Clin Oncol. 2025;43(23):2606\u201315. https:\/\/doi.org\/10.1200\/JCO-25-00914.","journal-title":"J Clin Oncol"},{"key":"146_CR77","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1182\/blood-2024-199170","volume":"144","author":"AT Fathi","year":"2024","unstructured":"Fathi AT, Issa GC, Wang ES, Erba H, Altman JK, Balasubramanian SK, et al. Ziftomenib combined with venetoclax\/azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007. Blood. 2024;144:2880. https:\/\/doi.org\/10.1182\/blood-2024-199170.","journal-title":"Blood"},{"key":"146_CR78","unstructured":"Berberabe T. Expanding menin inhibitors in acute myeloid leukemia. Target Oncol. 2025. Available at: TargetedOnc.com. Accessed 5 June 2026."},{"key":"146_CR79","doi-asserted-by":"publisher","unstructured":"Bazinet A, et al. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024;11(4):e287\u201398. https:\/\/doi.org\/10.1016\/S2352-3026(24)00034-6. ClinicalTrials.govIdentifier:NCT06852222.","DOI":"10.1016\/S2352-3026(24)00034-6"},{"issue":"4","key":"146_CR80","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","volume":"8","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, et al. Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024;8(4):978\u201390. https:\/\/doi.org\/10.1182\/bloodadvances.2023012120.","journal-title":"Blood Adv"},{"key":"146_CR81","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1182\/blood-2024-205980","volume":"144","author":"AS Stein","year":"2024","unstructured":"Stein AS, et al. Phase 1 trial of navitoclax\/venetoclax\/decitabine combination in relapsed\/refractory (R\/R) acute myeloid leukemia (AML). Blood. 2024;144:4264. https:\/\/doi.org\/10.1182\/blood-2024-205980.","journal-title":"Blood"},{"key":"146_CR82","unstructured":"ClinicalTrials.gov. Navitoclax, venetoclax, and decitabine for the treatment of relapsed or refractory acute myeloid leukemia previously treated with venetoclax. ClinicalTrials.gov identifier: NCT05222984. Sponsor: National Cancer Institute. Available at: ClinicalTrials.gov. Accessed 5 June 2026."},{"issue":"2","key":"146_CR83","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/hematolrep16020024","volume":"16","author":"A Candoni","year":"2024","unstructured":"Candoni A, Coppola G. A 2024 update on menin inhibitors: a new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia. Hematol Rep. 2024;16(2):244\u201354. https:\/\/doi.org\/10.3390\/hematolrep16020024.","journal-title":"Hematol Rep"},{"key":"146_CR84","doi-asserted-by":"publisher","unstructured":"Dhiman S, et al. Targeting menin in acute myeloid leukemia. Therapeutic advances and future directions. Cancers (Basel). 2024;16(22):3743, 3743. https:\/\/doi.org\/10.3390\/cancers16223743.","DOI":"10.3390\/cancers16223743"},{"key":"146_CR85","doi-asserted-by":"publisher","unstructured":"Salman MY, Stein EM. Revumenib for patients with acute leukemia: a new tool for differentiation therapy. Haematologica. 2024;109(11):3488\u201395. https:\/\/doi.org\/10.3324\/haematol.2022.282621.","DOI":"10.3324\/haematol.2022.282621"},{"key":"146_CR86","doi-asserted-by":"publisher","unstructured":"Issa GC, Aldoss I, Thirman MJ, Arellano ML, Perl AE, Dickens DS, et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43(1):75\u201384. https:\/\/doi.org\/10.1200\/JCO.24.00826.","DOI":"10.1200\/JCO.24.00826"},{"issue":"31","key":"146_CR87","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO-25-01694","volume":"43","author":"ES Wang","year":"2025","unstructured":"Wang ES, et al. Ziftomenib in relapsed or refractory NPM1-mutated AML. J Clin Oncol. 2025;43(31):3381\u201390. https:\/\/doi.org\/10.1200\/JCO-25-01694.","journal-title":"J Clin Oncol"},{"key":"146_CR88","unstructured":"U.S. Food and Drug Administration. FDA approval of revumenib for KMT2A-rearranged leukemia. 2024."},{"key":"146_CR89","unstructured":"U.S. Food and Drug Administration. FDA approval of revumenib for NPM1-mutated acute myeloid leukemia. 2025."},{"key":"146_CR90","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, et al. Revumenib first-in-human study. Nature. 2023;615:920\u20138.","journal-title":"Nature"},{"key":"146_CR91","doi-asserted-by":"publisher","unstructured":"Aldoss I, Issa GC, Blachly J, Thirman M, Mannis G, Arellano M, et al. Revumenib for patients with relapsed or refractory (R\/R) KMT2A-rearranged acute leukemia: outcomes by leukemia type in the phase 2 AUGMENT-101 study. Blood. 2025;146(Suppl 1):1001. https:\/\/doi.org\/10.1182\/blood-2025-1001.","DOI":"10.1182\/blood-2025-1001"},{"key":"146_CR92","doi-asserted-by":"publisher","unstructured":"Arellano ML, Thirman MJ, DiPersio JF, Heiblig M, Stein EM, Schuh AC, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025;146(9):1065\u201377. https:\/\/doi.org\/10.1182\/blood.2025028357.","DOI":"10.1182\/blood.2025028357"},{"key":"146_CR93","unstructured":"Syndax Pharmaceuticals, Inc. REVUFORJ\u00ae (revumenib) tablets, for oral use: US prescribing information. Waltham, MA: Syndax Pharmaceuticals, Inc.; 2025. Kura Oncology, Inc. KOMZIFTI\u2122 (ziftomenib) capsules, for oral use: US prescribing information. Boston, MA: Kura Oncology, Inc.; 2025. Available at: Drugs@FDA . Accessed 5 June 2026."},{"key":"146_CR94","unstructured":"U.S. Food and Drug Administration. FDA approval of ziftomenib. 2025."},{"key":"146_CR95","unstructured":"AML Hub. KOMET-001 updates. 2025."},{"key":"146_CR96","doi-asserted-by":"publisher","unstructured":"Wang ES, Montesinos P, Foran JM, et al. Ziftomenib in relapsed\/refractory NPM1-mutant acute myeloid leukemia: phase 1b\/2 results from the pivotal KOMET-001 study. J Clin Oncol. 2025;43(16 Suppl):6506. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.6506.","DOI":"10.1200\/JCO.2025.43.16_suppl.6506"},{"issue":"Suppl 1","key":"146_CR97","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood-2023-172422","volume":"142","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, et al. A first-in-human phase 1 study of the menin\u2013KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed\/refractory acute leukemia harboring KMT2A or NPM1 alterations. Blood. 2023;142(Suppl 1):57. https:\/\/doi.org\/10.1182\/blood-2023-172422.","journal-title":"Blood"},{"key":"146_CR98","unstructured":"ClinicalTrials.gov. A study of bleximenib in combination with acute myeloid leukemia-directed therapies. ClinicalTrials.gov identifier: NCT05453903. Sponsor: Janssen Research & Development, LLC. Available at: ClinicalTrials.gov. Accessed 5 June 2026."},{"issue":"Suppl 1","key":"146_CR99","doi-asserted-by":"publisher","first-page":"5200","DOI":"10.1182\/blood-2025-5200","volume":"146","author":"J O\u2019Nions","year":"2025","unstructured":"O\u2019Nions J, Wei A, Esteve J, et al. Phase 1b study of bleximenib in combination with venetoclax in acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2025;146(Suppl 1):5200. https:\/\/doi.org\/10.1182\/blood-2025-5200.","journal-title":"Blood"},{"issue":"Suppl 1","key":"146_CR100","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1182\/blood-2025-5199","volume":"146","author":"H D\u00f6hner","year":"2025","unstructured":"D\u00f6hner H, Schuh A, Recher C, et al. Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2025;146(Suppl 1):5199. https:\/\/doi.org\/10.1182\/blood-2025-5199.","journal-title":"Blood"},{"key":"146_CR101","unstructured":"ClinicalTrials.gov. A phase 1\/2 study of bleximenib in participants with acute leukemia (cAMeLot-1). ClinicalTrials.gov identifier: NCT04811560. Sponsor: Janssen Research & Development, LLC. Available at: ClinicalTrials.gov. Accessed 5 June 2026."},{"key":"146_CR102","unstructured":"Johnson & Johnson. Bleximenib press release. 2025."},{"key":"146_CR103","unstructured":"ClinicalTrials.gov. A phase 1\/2, open-label, dose-escalation, dose-expansion study of enzomenib (DSP-5336) in patients with acute leukemia and other selected hematologic malignancies, with and without mixed lineage leukemia (MLL) rearrangement or nucleophosmin 1 (NPM1) mutation (HORIZON-1). ClinicalTrials.gov identifier: NCT04988555. Sponsor: Sumitomo Pharma America, Inc. Available at: ClinicalTrials.gov. Accessed 5 June 2026."},{"issue":"Suppl 1","key":"146_CR104","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood-2024-194827","volume":"144","author":"JF Zeidner","year":"2024","unstructured":"Zeidner JF, Yuda J, Watts JM, et al. First-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2024;144(Suppl 1):213. https:\/\/doi.org\/10.1182\/blood-2024-194827.","journal-title":"Blood"},{"issue":"Suppl 1","key":"146_CR105","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2025-763","volume":"146","author":"NG Daver","year":"2025","unstructured":"Daver NG, et al. Monotherapy update from the phase 1 portion of a phase 1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2025;146(Suppl 1):763. https:\/\/doi.org\/10.1182\/blood-2025-763.","journal-title":"Blood"},{"issue":"Suppl 1","key":"146_CR106","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1182\/blood-2025-765","volume":"146","author":"JM Watts","year":"2025","unstructured":"Watts JM, Borate U, Levis M, et al. Enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed\/refractory AML: preliminary phase 1 data. Blood. 2025;146(Suppl 1):765. https:\/\/doi.org\/10.1182\/blood-2025-765.","journal-title":"Blood"},{"key":"146_CR107","unstructured":"ClinicalTrials.gov. A phase I\/II, multicenter, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of the menin inhibitor BN104 in the treatment of patients with relapsed\/refractory acute leukemia. ClinicalTrials.gov identifier: NCT06052813. Sponsor: Institut de Recherches Internationales Servier. Available at: ClinicalTrials.gov. Accessed 5 June 2026."},{"key":"146_CR108","unstructured":"ClinicalTrials.gov. Phase 2 trial of BN104 as post-HSCT maintenance in acute leukemia. ClinicalTrials.gov identifier: NCT07101497. Sponsor: The First Affiliated Hospital of Soochow University. Available at: ClinicalTrials.gov. Accessed 5 June 2026."},{"key":"146_CR109","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2024-198959","volume":"144","author":"D Wu","year":"2024","unstructured":"Wu D, et al. A first-in-human phase 1\/2 study of the menin\u2013KMT2A (MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia. Blood. 2024;144:2879. https:\/\/doi.org\/10.1182\/blood-2024-198959.","journal-title":"Blood"},{"key":"146_CR110","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, et al. ALFA-0701 trial. Lancet. 2012;379:1508\u201316.","journal-title":"Lancet"},{"key":"146_CR111","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, et al. ALFA-0701 final updates. Haematologica. 2019;104:113\u20139.","journal-title":"Haematologica"},{"key":"146_CR112","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, et al. Meta-analysis of gemtuzumab ozogamicin. Lancet Oncol. 2014;15:986\u201396.","journal-title":"Lancet Oncol"},{"key":"146_CR113","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/ajh.23795","volume":"89","author":"G Borthakur","year":"2014","unstructured":"Borthakur G, et al. FLAG-GO in core-binding factor acute myeloid leukemia. Am J Hematol. 2014;89:964\u20138.","journal-title":"Am J Hematol"},{"issue":"6","key":"146_CR114","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41408-021-00503-6","volume":"11","author":"G Borthakur","year":"2021","unstructured":"Borthakur G, Kantarjian H. Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021;11:114.","journal-title":"Blood Cancer J"},{"issue":"6","key":"146_CR115","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1200\/JCO.19.01406","volume":"38","author":"AK Burnett","year":"2020","unstructured":"Burnett AK, Schlenk RF, Paschka P, et al. Gemtuzumab ozogamicin combined with intensive chemotherapy in NPM1-mutated acute myeloid leukemia: results from a randomized phase III trial. J Clin Oncol. 2020;38(6):623\u201332. https:\/\/doi.org\/10.1200\/JCO.19.01406.","journal-title":"J Clin Oncol"},{"key":"146_CR116","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, et al. Gemtuzumab ozogamicin exposure and veno-occlusive disease risk post-transplant. Blood. 2003;102:1578\u201382.","journal-title":"Blood"},{"key":"146_CR117","doi-asserted-by":"publisher","unstructured":"Swaminathan M, Cortes JE. Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia. Ther Adv Hematol. 2023;14:20406207231154708. https:\/\/doi.org\/10.1177\/20406207231154708.","DOI":"10.1177\/20406207231154708"},{"key":"146_CR118","first-page":"127","volume":"9","author":"J Baron","year":"2018","unstructured":"Baron J, et al. Gemtuzumab ozogamicin: ALFA-0701 analyses. Ther Adv Hematol. 2018;9:127\u201338.","journal-title":"Ther Adv Hematol"},{"key":"146_CR119","volume":"7","author":"RL Maute","year":"2022","unstructured":"Maute RL, et al. CD47\u2013SIRP\u03b1 therapeutics. ESMO Open. 2022;7:100463.","journal-title":"ESMO Open"},{"key":"146_CR120","doi-asserted-by":"publisher","unstructured":"Wu F, Li P, Wu D, Li Z, Song X, Zhang S, et al. Progress in cancer research on the regulator of phagocytosis CD47. Oncol Lett. 2024;27(5):201. https:\/\/doi.org\/10.3892\/ol.2024.14331.","DOI":"10.3892\/ol.2024.14331"},{"issue":"5","key":"146_CR121","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood.2024027408","volume":"146","author":"JF Zeidner","year":"2025","unstructured":"Zeidner JF, et al. Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025;146(5):590\u2013600. https:\/\/doi.org\/10.1182\/blood.2024027408.","journal-title":"Blood"},{"issue":"5","key":"146_CR122","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1182\/blood.2024027506","volume":"146","author":"NG Daver","year":"2025","unstructured":"Daver NG, et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood. 2025;146(5):601\u201311. https:\/\/doi.org\/10.1182\/blood.2024027506.","journal-title":"Blood"},{"key":"146_CR123","unstructured":"Gilead Sciences. ENHANCE-3 discontinuation and FDA clinical hold. 2024."},{"key":"146_CR124","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti S, et al. Immune escape in acute myeloid leukemia. Leukemia. 2022;36:2247\u201366.","journal-title":"Leukemia"},{"key":"146_CR125","unstructured":"Calis U, et al. PD-1\/PD-L1 in acute myeloid leukemia. 2025."},{"key":"146_CR126","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood.V126.23.122.122","volume":"126","author":"AD \u00d8rskov","year":"2015","unstructured":"\u00d8rskov AD, et al. Azacitidine up-regulates PD-1. Blood. 2015;126:122\u201331.","journal-title":"Blood"},{"key":"146_CR127","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, et al. Azacitidine with or without durvalumab. Blood Adv. 2022;6:2219\u201329.","journal-title":"Blood Adv"},{"issue":"12","key":"146_CR128","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.3324\/haematol.2024.285313","volume":"109","author":"K Quann","year":"2024","unstructured":"Quann K, Lontos K, Sehgal A, Raptis A, Im A, Redner RL, et al. A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia. Haematologica. 2024;109(12):4106\u201311. https:\/\/doi.org\/10.3324\/haematol.2024.285313.","journal-title":"Haematologica"},{"issue":"9","key":"146_CR129","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/bloodadvances.2024015176","volume":"9","author":"AR Pyzer","year":"2025","unstructured":"Pyzer AR, et al. Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025;9(9):2144\u201352. https:\/\/doi.org\/10.1182\/bloodadvances.2024015176.","journal-title":"Blood Adv"},{"key":"146_CR130","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids MS, et al. Ipilimumab for relapse after allogeneic transplantation. N Engl J Med. 2016;375:143\u201353.","journal-title":"N Engl J Med"},{"key":"146_CR131","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, et al. Azacitidine plus nivolumab in relapsed acute myeloid leukemia. Cancer Discov. 2019;9:370\u201383.","journal-title":"Cancer Discov"},{"key":"146_CR132","unstructured":"U.S. Food and Drug Administration. ELZONRIS (tagraxofusp-erzs) injection, prescribing information. 2018."},{"key":"146_CR133","doi-asserted-by":"publisher","unstructured":"Lane AA, et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024;13(8):591\u2013602. https:\/\/doi.org\/10.1182\/bloodadvances.2023011721. ClinicalTrials.govIdentifier:NCT03113643.","DOI":"10.1182\/bloodadvances.2023011721"},{"issue":"1","key":"146_CR134","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3234","volume":"42","author":"A Bruzzese","year":"2024","unstructured":"Bruzzese A, Martino EA, Labanca C, et al. Tagraxofusp in myeloid malignancies. Hematol Oncol. 2024;42(1):e3234. https:\/\/doi.org\/10.1002\/hon.3234.","journal-title":"Hematol Oncol"},{"issue":"2","key":"146_CR135","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70063","volume":"9","author":"B Watts","year":"2025","unstructured":"Watts B, Szymanska B, Kang H, Lock RB. The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia. HemaSphere. 2025;9(2):e70063. https:\/\/doi.org\/10.1002\/hem3.70063.","journal-title":"HemaSphere"},{"issue":"3","key":"146_CR136","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","volume":"25","author":"NG Daver","year":"2024","unstructured":"Daver NG, Montesinos P, DeAngelo DJ, et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study. Lancet Oncol. 2024;25(3):388\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(23)00674-5.","journal-title":"Lancet Oncol"},{"key":"146_CR137","doi-asserted-by":"crossref","unstructured":"Daver N, Rausch CR, Garcia-Manero G, et al. Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed acute myeloid leukemia. Blood. 2025;146(Suppl 1):651.","DOI":"10.1182\/blood-2025-651"},{"issue":"21","key":"146_CR138","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","volume":"7","author":"F Ravandi","year":"2023","unstructured":"Ravandi F, et al. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia. Blood Adv. 2023;7(21):6492\u2013505. https:\/\/doi.org\/10.1182\/bloodadvances.2023010956.","journal-title":"Blood Adv"},{"issue":"1","key":"146_CR139","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1038\/s41467-025-63069-y","volume":"16","author":"N Schmitt","year":"2025","unstructured":"Schmitt N, Siegler JJ, Beck A, et al. The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. Nat Commun. 2025;16(1):7793. https:\/\/doi.org\/10.1038\/s41467-025-63069-y.","journal-title":"Nat Commun"},{"key":"146_CR140","doi-asserted-by":"publisher","unstructured":"Montesinos P, Arn\u00e1n M, de Botton S, Calbacho M, Vydra J, Watts JM, et al. Engaging innate immunity by AFM28, an innate cell engager (ICE\u00ae) targeting CD123-positive leukemic cells in patients with relapsed\/refractory acute myeloid leukemia: safety and efficacy results of a first-in-human phase 1 study. Blood. 2024;144(Suppl 1):738. https:\/\/doi.org\/10.1182\/blood-2024-194356.","DOI":"10.1182\/blood-2024-194356"},{"issue":"6","key":"146_CR141","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/curroncol32060322","volume":"32","author":"P Lloret-Madrid","year":"2025","unstructured":"Lloret-Madrid P, Chor\u00e3o P, Guerreiro M, Montesinos P. CAR-T cell therapy for acute myeloid leukemia: where do we stand now? Curr Oncol. 2025;32(6):322. https:\/\/doi.org\/10.3390\/curroncol32060322.","journal-title":"Curr Oncol"},{"key":"146_CR142","doi-asserted-by":"publisher","unstructured":"Guijarro-Albaladejo B, Marrero-Cepeda C, Rodr\u00edguez-Arbol\u00ed E, Sierro-Mart\u00ednez B, P\u00e9rez-Sim\u00f3n JA, Garc\u00eda-Guerrero E. Chimeric antigen receptor (CAR) modified T cells in acute myeloid leukemia: limitations and expectations. Front Cell Dev Biol. 2024;12:1376554, 1376554. https:\/\/doi.org\/10.3389\/fcell.2024.1376554.","DOI":"10.3389\/fcell.2024.1376554"},{"key":"146_CR143","doi-asserted-by":"publisher","unstructured":"Jin X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88, 88. https:\/\/doi.org\/10.1186\/s13045-022-01308-1.","DOI":"10.1186\/s13045-022-01308-1"},{"issue":"11","key":"146_CR144","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia. 2021;35(11):3282\u20136. https:\/\/doi.org\/10.1038\/s41375-021-01232-2.","journal-title":"Leukemia"},{"issue":"1","key":"146_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory acute myeloid leukemia: preclinical evaluation and phase I trial. Exp Hematol Oncol. 2025;14(1):1. https:\/\/doi.org\/10.1186\/s40164-024-00592-6.","journal-title":"Exp Hematol Oncol"},{"key":"146_CR146","unstructured":"Ahmadvand M, et al. Allogeneic NK-cell trials in acute myeloid leukemia. 2023."},{"key":"146_CR147","doi-asserted-by":"publisher","unstructured":"Bakhtiyaridovvombaygi M, Kheyrandish S, Safdari SM, Eskandrian S, Rousta H, Hossaini D, et al. A systematic review of the last two decades of NK cell-based clinical trials: state of the art of AML therapy. BMC Cancer. 2025;25(1):1461, 1461. https:\/\/doi.org\/10.1186\/s12885-025-14837-y.","DOI":"10.1186\/s12885-025-14837-y"},{"key":"146_CR148","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40164-025-00651-6","volume":"14","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhu HH. CAR-T therapy in acute myeloid leukemia: ASH 2024 update. Exp Hematol Oncol. 2024;14:57.","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"146_CR149","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154334","volume":"132","author":"RM Shapiro","year":"2022","unstructured":"Shapiro RM, Birch GC, Hu G, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022;132(11):e154334. https:\/\/doi.org\/10.1172\/JCI154334.","journal-title":"J Clin Invest"},{"issue":"6","key":"146_CR150","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood.2020007732","volume":"137","author":"G Levy","year":"2021","unstructured":"Levy G, et al. Flotetuzumab in relapsed or refractory acute myeloid leukemia. Blood. 2021;137(6):751\u201362. https:\/\/doi.org\/10.1182\/blood.2020007732.","journal-title":"Blood"},{"key":"146_CR151","doi-asserted-by":"publisher","unstructured":"Ravandi F, Subklewe M, Walter RB, Vachhani P, Jabbour E, Olin RL, et al. Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study. Leuk Lymphoma. 2024;65(9):1281\u201391. https:\/\/doi.org\/10.1080\/10428194.2024.2346755.","DOI":"10.1080\/10428194.2024.2346755"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00146-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00146-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00146-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:54:31Z","timestamp":1781531671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00146-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["146"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00146-1","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}